Flozins under the microscope: can they protect heart and kidneys in High-Risk patients?
NCT ID NCT07237451
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study follows 200 adults with chronic kidney disease and a type of heart failure (HFpEF), some taking SGLT2 inhibitors (flozins) and some not. Researchers will measure arterial stiffness, heart function, and kidney decline over time to see if flozins are linked to better outcomes. The goal is to gather real-world evidence, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors (flozins)
- What this could lead to
- If successful, this study could clarify how SGLT2 inhibitors affect heart and kidney health in patients with chronic kidney disease and heart failure.
- What could go wrong
- This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. C.I. Parhon Hospital in Iasi
RECRUITINGIași, Romania
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Prescribing food: could a diet of medically tailored meals tame diabetes?
- Alexa, teach me about diabetes: smart speaker trial aims to improve blood sugar in older adults
- AI-Powered trial asks: does adding a second drug cut heart failure risk?
- Diabetes drug class may change how the bladder behaves